NASDAQ: TNFATnf Pharmaceuticals Inc Stock
$0.18-0.07 (-28%)
Updated Apr 17, 2025
TNFA Price
$0.18
Fair Value Price
N/A
Market Cap
$1.85M
52 Week Low
$0.17
52 Week High
$3.37
P/E
-0.02x
P/B
0.19x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$23.36M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.69
Operating Cash Flow
-$9M
Beta
0.97
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
TNFA Overview
TNF Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company. It focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms. Its MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. The MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases. The company's second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction, and epilepsy. The Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve the growing CBD market, which includes FDA approved drugs and CBD products not regulated as drugs. TNF Pharmaceuticals, Inc. was formerly known as MyMD Pharmaceuticals, Inc. and changed its name to TNF Pharmaceuticals, Inc. in July 2024. The company was founded in 2014 and is headquartered in Baltimore, Maryland.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine TNFA's potential to beat the market
- TNFA doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
TNFA
RankedUnranked of 463
RankedUnranked of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.61 | A | |
| $7.75 | A | |
| $16.85 | A |
Be the first to know about important TNFA news, forecast changes, insider trades & much more!
TNFA News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how TNFA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
TNFA is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
TNFA is good value based on its book value relative to its share price (0.19x), compared to the US Biotechnology industry average (4.05x)
P/B vs Industry Valuation
TNFA is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more TNFA due diligence checks available for Premium users.
Valuation
TNFA fair value
Fair Value of TNFA stock based on Discounted Cash Flow (DCF)
Price
$0.18
Fair Value
-$0.03
Undervalued by
703.52%
TNFA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
TNFA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.02x
Industry
-177.72x
Market
27.98x
TNFA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.19x
Industry
4.05x
TNFA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
TNFA's financial health
Profit margin
Revenue
$0.0
Net Income
-$2.1M
Profit Margin
0%
TNFA's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$21.4M
Liabilities
$6.7M
Debt to equity
0.69
TNFA's short-term assets ($9.41M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
TNFA's short-term assets ($9.41M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
TNFA's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
TNFA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$764.1k
Investing
$1.1M
Financing
-$1.4M
TNFA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
TNFA vs Biotech Stocks
Tnf Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.